Nuveen LLC Makes New $2.02 Million Investment in Vanda Pharmaceuticals Inc. $VNDA

Key Points

• Nuveen LLC has acquired 440,561 shares of Vanda Pharmaceuticals, representing a 0.75% ownership stake, valued at approximately $2,022,000.
• Vanda Pharmaceuticals reported a loss of $0.46 earnings per share (EPS) for its last quarter, which was below analysts' expectations of $0.34 EPS.
• Research firms have varying outlooks on Vanda, with HC Wainwright issuing a "buy" rating and a target price of $20.00, while Wall Street Zen has downgraded the stock to a "strong sell" rating.

Nuveen LLC bought a new position in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 440,561 shares of the biopharmaceutical company's stock, valued at approximately $2,022,000. Nuveen LLC owned about 0.75% of Vanda Pharmaceuticals at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Quantinno Capital Management LP acquired a new position in shares of Vanda Pharmaceuticals during the fourth quarter valued at about $48,000. Linden Thomas Advisory Services LLC acquired a new position in shares of Vanda Pharmaceuticals during the first quarter valued at about $49,000. Virtu Financial LLC acquired a new position in shares of Vanda Pharmaceuticals during the first quarter valued at about $72,000. ProShare Advisors LLC raised its position in shares of Vanda Pharmaceuticals by 32.4% during the fourth quarter. ProShare Advisors LLC now owns 18,815 shares of the biopharmaceutical company's stock valued at $90,000 after buying an additional 4,599 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD raised its position in shares of Vanda Pharmaceuticals by 17.8% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 22,265 shares of the biopharmaceutical company's stock valued at $107,000 after buying an additional 3,370 shares during the last quarter. Institutional investors and hedge funds own 88.14% of the company's stock.

Vanda Pharmaceuticals Trading Down 1.8%

NASDAQ VNDA traded down $0.09 on Thursday, reaching $4.64. The company's stock had a trading volume of 58,643 shares, compared to its average volume of 558,704. The firm has a market cap of $273.88 million, a PE ratio of -4.10 and a beta of 0.74. The business has a 50-day moving average price of $4.64 and a 200 day moving average price of $4.53. Vanda Pharmaceuticals Inc. has a 52 week low of $3.81 and a 52 week high of $5.55.

Vanda Pharmaceuticals (NASDAQ:VNDA - Get Free Report) last issued its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.34) by ($0.12). The firm had revenue of $52.59 million for the quarter, compared to the consensus estimate of $54.77 million. Vanda Pharmaceuticals had a negative return on equity of 12.89% and a negative net margin of 32.90%. Vanda Pharmaceuticals has set its FY 2025 guidance at EPS. Analysts anticipate that Vanda Pharmaceuticals Inc. will post -1.12 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have recently commented on VNDA shares. Wall Street Zen lowered shares of Vanda Pharmaceuticals from a "hold" rating to a "strong sell" rating in a research report on Saturday, August 2nd. Cantor Fitzgerald reissued an "overweight" rating and issued a $13.00 target price on shares of Vanda Pharmaceuticals in a research note on Wednesday, May 14th. Finally, HC Wainwright reissued a "buy" rating and issued a $20.00 target price on shares of Vanda Pharmaceuticals in a research note on Thursday, August 21st. One analyst has rated the stock with a Strong Buy rating and one has given a Buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Strong Buy" and an average price target of $16.50.

Insiders Place Their Bets

In other Vanda Pharmaceuticals news, Director Stephen Ray Mitchell sold 7,000 shares of the company's stock in a transaction dated Friday, June 13th. The shares were sold at an average price of $4.59, for a total transaction of $32,130.00. Following the sale, the director directly owned 97,082 shares of the company's stock, valued at approximately $445,606.38. This represents a 6.73% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 8.90% of the company's stock.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.